Adverse reactions
observed during clinical trials include vomiting, increased liver enzymes and transient loss of hearing.
Not exact matches
In addition, the molecule has already undergone a phase III
clinical trial during which no toxicity was
observed, prompting researchers to select it, even though its indication and administration route will be different than previously envisaged.
Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data
observed during preclinical or
clinical studies,
clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of Syndax's collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes.